Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 17/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.77 |
| ▸ | SLC2A9 | Q9NRM0 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28666334 | 0.89 | SLC22A12 (0.61) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL13445215 | 0.89 | SLC22A12 (0.64) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL4736274 | 0.88 | SLC22A12 (0.76) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL10008679 | 0.88 | SLC22A12 (0.78) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL13444978 | 0.87 | SLC22A12 (0.77) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| Lesinurad SCHEMBL842962 | 0.87 | SLC22A12 (1.00) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL879017 | 0.87 | SLC22A12 (0.77) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL15555942 | 0.87 | SLC22A12 (0.77) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| Lesinurad SCHEMBL29353441 | 0.87 | SLC22A12 (1.00) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL13445220 | 0.86 | SLC22A12 (0.73) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183012-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20160221970-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160221970-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2016-08-04 | — | — | US | disclosed |
| EP-2217577-B1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES INC (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2014008295-A1 | MANUFACTURE OF 2- (5- BROMO-4 (-CYCLOPROPYLNAPHTHALEN-1-YL) -4H-1,2,4-TRIAZOL-3-YLTHIO) ACETIC ACID | ARDEA BIOSCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| US-8546437-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546437-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8357713-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120164222-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120164222-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8084483-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084483-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110293719-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110293719-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120164222-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-10183012-B2 | Compounds and compositions and methods of use | XDH, PON1, OAT | SLC22A12 815/4885CYP2C9 762/4885CYP2C19 905/4885 |
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-20160221970-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
| US-20110293719-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C9 1526/4885CYP2C19 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.